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Smqnr VARIANTS IN CLINICAL ISOLATES OF Stenotrophomonas maltophilia IN BRAZIL
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SUMMARY
Stenotrophomonas maltophilia contains a novel chromosomally-encoded qnr gene named Smqnr that contributes to low intrinsic 
resistance to quinolone. We described Smqnr in 13 clinical isolates of S. maltophilia from two Brazilian hospitals, over a 2-year 
period. The strains were identified by API 20 NE (bioMérieux, France). Susceptibility by microdilution method to trimetroprim/
sulfamethoxazole, ciprofloxacin, levofloxacin, minocycline, ceftazidime, chloramphenicol and ticarcillin/clavulanate was performed 
according to CLSI. PCR detection of Smqnr gene was carried out. The sequence of Smqnr was compared with those deposited in 
GenBank. Pulsed-field gel electrophoresis (PFGE) of all strains was performed. Thirteen Smqnr positives isolates were sequenced 
and three novel variants of Smqnr were identified. All 13 Smqnr isolates had distinguishable patterns by PFGE. This is the first report 
of Smqnr in S. maltophilia isolated in Brazil. 
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INTRODUCTION
Stenotrophomonas maltophilia, a non-fermentative Gram-negative 
bacillus that is ubiquitous in the environment, has emerged as an 
important opportunistic pathogen2. This microorganism exhibits intrinsic 
and acquired resistance to a wide variety of antimicrobial agents 
and few options of treatment are available2,15. So far, trimethoprim/
sulfamethoxazole is the drug of choice to treat infections caused by this 
microorganism, however, during the past few years increased resistance 
to this antibiotic has been reported8,15. The new fluoroquinolones such as 
levofloxacin and moxifloxacin showed promising in vitro activity against 
S. maltophilia13. Resistance to these new fluoroquinolones, among S. 
matophilia, is rare and needs to be further researched. 
S. maltophilia contains a novel chromosomally-encoded S. 
maltophilia qnr gene named Smqnr with 219 amino acids with two 
classic pentapeptide repeat motifs separated by a glycine residue, which 
confers low level resistance to quinolone antibiotics as showed in vitro 
experiments12. The role of Smqnr on quinolones resistance, however, is 
controversial and there is a lack of research evaluating its association 
with levofloxacin resistance in S. maltophilia. 
We describe the characterization of Smqnr genes in clinical isolates of 
S. maltophilia susceptible and resistant to ciprofloxacin and levofloxacin. 
MATERIAL AND METHODS
Clinical samples of S. maltophilia isolates from two Brazilian teaching 
hospitals, over a 2-year period were evaluated. Isolates were identified 
by API 20 NE (bioMérieux, France). Susceptibility by microdilution 
method to trimethoprim/sulfamethoxazole, ciprofloxacin, levofloxacin, 
minocycline, ceftazidime, chloramphenicol and ticarcillin/clavulanate 
was performed according to the CLSI (CLSI 2011)4. Tigecycline MIC 
was interpreted following the Food and Drug Administration (FDA) 
recommendation for Enterobacteriaceae. Endonuclease-digested 
genomic DNAs were separated by pulsed-field gel electrophoresis 
(PFGE) using a CHEF-DR III system (Bio-Rad, USA). Genomic DNA 
was digested with 10U of SpeI (fermentas, USA). Running conditions 
were 21 h at 14 °C, with and initial switching time of one s and final 
time of 30 s, at 6 V/cm. 
PCR for the Smqnr gene was carried out using five different set 
of specific sequence primers QnrM+ (5’-CTTGGCATGGAATCCC 
TGAT-3’)/QnrM- (5’-TGATGCCTACGGCACCAC-3’), QnrMR55+ 
(5’-CATGGCATGGAATCCCCGAT-3’)/QnrMR55- (5’-TGATG 
TCTACGGCACCAC-3’), qnrA (F:5’-CTCGAATGCCTGGCGCG 
TGTTT-3’) (R: 5’- AAGAGATTTCTCAGCCAGG-3’), qnrB (F: 
5’-TGCCAGGCACAGATCTTGAC-3’) (R: AGGMATHGAAATTCG 
CCACTG-3’) and qnrS (F: 5’- TTTGCYGYYCGCCAGTCGAA-3’) 
(R:5’:GCAAGTTCATTGAACAGGGT-3’) and was performed in accor-
dance with SANCHEZ et al. (2008) and ROBICSEK et al. (2006)10,11. 
We used five set of primers because the regions around qnr are different 
in the sequences of S. maltophilia strains K279a, R551-3 and qnr A, B, 
S of Enterobacteriaceae species.
The nucleotide sequences and the deduced amino acid sequence were 
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analyzed using the biological sequence aligment editor and CLUSTALW 
(www.mbio.ncsu.edu/bioedit/bioedit) (CA, USA). 
This study was approved by the Ethics Committee of the two 
hospitals.
RESULTS
Thirteen S. maltophilia isolates harboring Smqnr were studied, 
eight resistant to ciprofloxacin and two to levofloxacin. QnrM gene was 
detected only using primers derived from S. maltophilia strain K279a; 
qnr A, B and S genes of Enterobacteriaceae were not detected. 
All 13 isolates showed distinguishable patterns by PFGE (Table 1). 
The distribution of isolates occurred evenly in different units and with 
different clonal profiles during the study period, which ruled out the 
possibility of an outbreak.
Two of the 13 isolates were resistant (MIC 8 and 16 mg/L) and two 
showed increased MIC to levofloxacin (MIC 4 mg/L). Eight isolates 
were resistant and one exhibited increased MIC to ciprofloxacin (MIC ≥ 
2 mg/L). Two isolates were resistant to trimethoprim/sulfamethoxazole 
(MIC 4 and 8 mg/L). Two isolates were resistant to tigecycline (MIC 4 
and 8 mg/L) and all isolates were susceptible to minocycline (MIC < 4 
mg/L) (Table 1).
The Smqnr peptide sequences of the 13 isolates were compared 
with the known Smqnr 1-27 subtypes in GenBank. Sequence analysis 
showed that seven isolates were identical to the equivalent sequence of 
Smqnr6 from Japan (AB430849), the other isolates were distributed as 
followed: one Smqnr4 (GenBank AB430842), one Smqnr12 (GenBank 
AB430844) and one Smqnr1 (Genbank AB430839) identified in Japan. 
Three novel variants were observed, the subtype SmqnrLIM31 have six 
amino acid residues differences, the subtype SmqnrLIM39 have four 
amino acid residues differences and subtype SmqnrLIM45 showed two 
amino acids alteration (Fig. 1). 
DISCUSSION
S. maltophilia strains display high ciprofloxacin resistance, mainly 
due to several efflux systems1. However, in vitro, susceptibility testing 
to levofloxacin is recommended by CLSI (CLSI 2009), and levofloxacin 
and moxifloxacin are used to treat infections caused by this pathogen. 
Resistance to levofloxacin and moxifloxacin is still rare among S. 
maltophilia5,14. Two recent studies of clinical isolates of S. maltophilia 
that evaluated 102 isolates of bloodstream infection and 377 isolates 
(majority from the respiratory tract and blood) showed respectively 92.9% 
and 79.6% of susceptibility to levofloxacin5,14. In our study two isolates 
showed resistance and two increased MIC to levofloxacin. All isolates 
were susceptible to minocycline and two were resistant to trimethoprim/
sulfamethoxazole. Despite good activity in vitro, the experience of the 
clinical use of minocycline to treat infections caused by S. maltophilia 
is restricted to anecdotal reports7.
The Smqnr plasmid mediated genes are pentapeptides repeat 
proteins that confer low-level resistance to quinolone by protecting DNA 
gyrase. The potential source of qnr is believe to be horizontal transfer 
by integrons and mobile genetic elements from chromosome of aquatic 
or environmental bacterial, such Shewanella algae, Aeromonas spp., 
Psychromonas spp and Vibrionaceae14.
Table 1
Characteristics and antimicrobial susceptibilities of 13 clinical isolates of S. maltophilia 
Isolates Source PFGE
MIC (mg/L)
SMX LEV CIP MIN TIG CAZ CLO TIC
LIM7 Blood A 0.5 1 8 <0.25 0.5 64 8 8
LIM9 Blood B 2 2 8 0.5 1 32 8 8
LIM11 Blood C 2 <0.25 1 0.25 0.25 32 8 >128
LIM14 CVC D <0.25 <0.25 0.5 0.25 0.25 >128 8 32
LIM31 CVC E <0.25 1 2 <0.25 0.5 4 32 32
LIM33 CVC F 1 16 64 2 4 16 32 64
LIM35 CVC G 0.5 0.25 4 <0.25 0.25 >128 16 128
LIM37 CVC H 0.25 0.5 8 <0.25 2 128 16 32
LIM39 CVC I 0.5 4 16 4 2 8 64 128
LIM41 CVC J 8 8 32 2 8 64 128 32
LIM45 BAL K 4 0.5 2 0.5 2 64 >128 128
LIM47 Blood L 0.5 1 1 <0.25 2 4 32 32
LIM49 Blood M 1 4 16 <0.25 1 8 128 >128
MIC, microdilutional method; BAL, Bronchoalveolar lavage; CVC, cateter venous central; PFGE, Pulsed field gel electrophoresis; SXT, trimethoprim/sulfamethoxa-
zole; LEV, levofloxacin; CIP, ciprofloxacin; MIN, minocycline; TIG, tigecycline; CAZ, ceftazidime; CLO,chloramphenicol; TIC, ticarcillin/clavulanate. PFGE: 13 
distinguishable patterns (letter A to M).
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The qnr genes in S. maltophilia isolates have been studied by some 
authors3,6,17,18. In our study, among 13 isolates harboring Smqnr; two 
were resistant (MIC 8 and 16 mg/L) and two exhibited increased MIC 
to levofloxacin (MIC 4 mg/L) and eight isolates exhibited resistant to 
ciprofloxacin. Three new Smqnr variants were identified. Two (LIM31 
and LIM45) of them presented high levofloxacin MIC. The isolates were 
polyclonal, showing that they did not have a clonal relationship. This is the 
first study that reports Smqnr in S. maltophilia clinical isolates in Brazil.
One important limitation of our study is that we were not able to 
perform cloning and transformation assays to confirm the role of Smqnr 
on fluorquinolone resistance in S. maltophilia.
The role of Smqnr on quinolones resistance among S. maltophilia, 
remains controversial, and appears to be associated with the clonality of 
strains and varies with the hospital and country. A recent study conducted 
in China, evaluated 442 clinical isolates of S. maltophilia from nine 
hospitals. The resistance against co-trimoxazole was 48.6%, and a high 
susceptibility was shown to levofloxacin, only 6.1% of strains were resistant 
to levofloxacin18. Smqnr genes were detected in 114 (26%) isolates in 
similar frequency in both quinolones sensitive and nonsensitive strains. 
Twenty new variants of Smqnr genes were identified and called Smqnr 
(28-47)18. An in vitro study, showed that overexpression of Smqnr upon 
deletion increased modestly the MIC of nalidixic acid and moxifloxacin3. 
And finally, a study conducted in the UK, identified two new variants of 
Smqnr that when expressed in E. coli top10 showed reduced susceptibility 
to several quinolone including levofloxacin and moxifloxacin16. 
In conclusion, this is the first report of the presence of Smqnr in 
isolates of S. matophilia resistant or with high levofloxacin MIC in 
Brazil. Three new Smqnr variants were identified. These findings alert 
the clinicians to the emergence of resistance to this antibiotic that is 
widely used in the treatment of infections by this agent, and strengthens 
the role of Smqnr with levofloxacin resistance. In addition, minocycline 
presented good activity in vitro against multidrug resistant strains of S. 
maltophilia and, in the future, may be an option for the treatment of 
infections caused by this agent. 
RESUMO
Variantes de Smqnr de isolados clínicos de Stenotrophomonas 
maltophilia no Brasil
S. maltophilia contem um novo gene qnr cromossômico denominado 
Smqnr que contribui para baixa resistência intrínseca a quinolonas. 
Descrevemos Smqnr em 13 isolados clínicos de S. maltophilia de dois 
hospitais brasileiros, ao longo do período de dois anos. Os isolados foram 
identificados pela API 20 NE (bioMérieux, França). Susceptibilidade 
pelo método de microdiluição dos seguintes antibióticos trimetroprim/
sulfametoxazol, ciprofloxacina, levofloxacina, minociclina, ceftazidima, 
cloranfenicol e ticarcilina/clavulanato foi realizada segundo o CLSI. 
Detecção do gene de Smqnr foi realizada por PCR. A sequência de Smqnr 
foi comparada com aquelas depositadas no GenBank. Foi realizada 
eletroforese em gel de campo pulsado (PFGE) de todos os isolados. 
Treze isolados contendo Smqnr foram sequenciados e identificados três 
variantes do gene Smqnr. Todos os 13 isolados de Smqnr apresentaram 
diferentes padrões por PFGE. Este é o primeiro relato de Smqnr em 
isolados de S. maltophilia no Brasil.
Fig. 1 - Aminoacid sequence alignments of 13 SmQnr proteins from Brazil, SmQnr1 
(SHIMIZU et al.) and SmQnr 13 (GORDON et al). Asterisks, identical aminoacids, colons, 
strongly similar aminoacids (conserved substitutions); full stops, weakly similar amino 
acids (semi-conserver substitutions); spaces, variable aminoacids. Amino acid differences 
are shown in redbold.
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